Skip to Content

Mylotarg (gemtuzumab) Disease Interactions

There are 4 disease interactions with Mylotarg (gemtuzumab):


Gemtuzumab ozogamicin (applies to Mylotarg) hepatic impairment/toxicity

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of gemtuzumab ozogamicin as a single agent, and as part of a combination chemotherapy regimen. Patients who had moderate/severe hepatic impairment prior to treatment were 8.7 times more likely to develop VOD compared to patients without moderate/severe hepatic impairment at baseline. Caution is advised in patients with hepatic impairment, with close monitoring of ALT, AST, total bilirubin, and alkaline phosphatase prior to each dose. After treatment, signs and symptoms of VOD should be monitored frequently; these may include elevations in ALT, AST, total bilirubin, hepatomegaly (which may be painful), rapid weight gain, and ascites. Monitoring only total bilirubin may not identify all patients at risk of VOD. For patients who develop abnormal liver tests, more frequent monitoring of liver tests and clinical signs and symptoms of hepatotoxicity is recommended. Treatment should be discontinued in patients that develop VOD.


Gemtuzumab ozogamicin (applies to Mylotarg) cytopenias

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Anemia, Bone Marrow Depression/Low Blood Counts

Gemtuzumab ozogamicin is a myelosuppressive agent. Assess blood counts prior to each dose and monitor blood counts frequently after treatment until resolution of cytopenias. Monitor patients for signs and symptoms of bleeding during treatment with gemtuzumab ozogamicin . Manage severe bleeding, hemorrhage or persistent thrombocytopenia using dose delay or permanent discontinuation of treatment, and provide supportive care per standard practice.


Gemtuzumab ozogamicin (applies to Mylotarg) QT prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome, Electrolyte Abnormalities

QT interval prolongation has been observed in patients treated with drugs containing calicheamicin. When administering gemtuzumab ozogamicin to patients who have a history of or predisposition for QTc prolongation, who are taking medicinal products that are known to prolong QT interval, and in patients with electrolyte disturbances, obtain electrocardiograms (ECGs) and electrolytes prior to the start of treatment and as needed during administration.


Gemtuzumab ozogamicin (applies to Mylotarg) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The pharmacokinetics of gemtuzumab ozogamicin in patients with severe renal impairment (CrCL 15-29 mL/min) is unknown. Caution is advised if used on these patients.

Mylotarg (gemtuzumab) drug interactions

There are 160 drug interactions with Mylotarg (gemtuzumab)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.